Merck: Keytruda approved for pleural mesothelioma

(CercleFinance.com) - Merck announces that the U.
S. FDA has approved its Keytruda, in combination with pemetrexed and platinum-based chemotherapy, for the first-line treatment of adults with unresectable advanced or metastatic malignant pleural mesothelioma.

Pleural mesothelioma, which develops in the lining of the lungs, accounts for around 75% of all cases of malignant mesothelioma, a type of cancer that originates in the lining of certain parts of the body.

This approval is based on the results of a Phase III trial, in which Keytruda combined with chemotherapy demonstrated a statistically significant improvement in overall survival compared with chemotherapy alone.

Copyright (c) 2024 CercleFinance.com. All rights reserved.